Ceritinib (Zykadia) 150mg*150's | Novartis China-Sourced | GLT

Generic Information: Zykadia (China-Mainland)

This is Novartis's originator ceritinib approved for the mainland China market, marketed there as Zykadia (赞可达). Each capsule contains 150 mg of ceritinib, and this large pack holds 150 capsules. The product is approved by China's National Medical Products Administration (NMPA) and is reimbursable through the national medical-insurance programme for eligible patients with ALK-positive lung cancer.

What Is Zykadia Used For?

In China, Zykadia is used for ALK-positive metastatic non-small cell lung cancer. It is prescribed for patients whose disease has progressed on crizotinib and, in line with the global label, as an initial targeted therapy for newly diagnosed ALK-positive NSCLC. For Chinese patients, the reimbursed status makes this originator drug far more accessible than in markets where it is paid out of pocket.

How Does Ceritinib Work?

Ceritinib is a second-generation ALK inhibitor. It blocks anaplastic lymphoma kinase, the abnormal signalling protein created by ALK gene rearrangements that drives a subset of lung cancers. Unlike first-generation crizotinib, ceritinib retains activity against many resistant ALK mutations, which is why it is effective after crizotinib stops working and as an upfront option for ALK-positive disease.

Indications

The approved indication is ALK-positive metastatic NSCLC, confirmed by a validated ALK test. Zykadia is used both after disease progression on crizotinib and as first-line treatment. Therapy is initiated and monitored by an oncology specialist, with routine imaging to assess response.

Dosage

The recommended dose is 450 mg (three capsules) once daily with food, or 750 mg once daily on an empty stomach as described in the original label. The 150-capsule pack provides one month of supply at the 450 mg daily dose or 30 days at 750 mg daily. Dosing is adjusted by the physician according to tolerance and liver-function results.

Side Effects

Common side effects are diarrhoea, nausea, vomiting, abdominal pain, fatigue and reduced appetite. More serious effects include liver enzyme elevations, hyperglycaemia, QT prolongation, and rare lung inflammation (pneumonitis). Patients are monitored for liver function, blood glucose and heart rhythm throughout treatment and should report persistent digestive symptoms or breathing difficulty immediately.

Storage

Store at room temperature in a dry place, keep capsules in the original packaging, and do not use after the expiry date.

Why Choose the China Version of Zykadia?

The China version of Zykadia is priced substantially below the same originator product in Western markets, and it is covered by China's national medical insurance for eligible patients. For overseas buyers sourcing through GLT, this translates into meaningful savings on genuine Novartis ceritinib — a 150-capsule monthly pack at a fraction of United States or European retail prices.

How to Order

Reach GLT on WhatsApp at +86 15234153837 or email [email protected] to order China-sourced Zykadia. We confirm current availability, pricing and shipping arrangements from our Hong Kong-licensed facility before you place an order.

FAQ

Is the China version the same as the Swiss version? Yes, both are Novartis originator ceritinib; the China version is the same formulation approved by the NMPA for the Chinese market.

Is Zykadia reimbursed in China? Yes, originator ceritinib has been included in China's national medical-insurance catalogue, so eligible patients with ALK-positive NSCLC can receive reimbursement.

How long does the 150-capsule pack last? One pack lasts about one month at the standard 450 mg once-daily dose.